Fig. 2

Main efficacy outcomes of SGLT2 inhibitors versus control. ESKD, death due to kidney disease, or sustained 40% decline in eGFR (Composite outcome A), ESKD, death due to kidney disease, or sustained decline eGFR of ≥50% from baseline (Composite outcome B), ESKD, death due to kidney disease, sustained decline in eGFR of ≥40% from baseline, or eGFR lower than 15 mL/min per 1.73 m² (Composite outcome C), ESKD, sustained decline in eGFR of ≥40% from baseline, or eGFR lower than 15 mL/min per 1.73 m² (Composite outcome D). eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; ESKD, end stage kidney disease, ESKD; SGLT2 inhibitors, Sodium-glucose cotransporter-2 inhibitors